Home › Research › Treatments
Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy
Patwekar F, Patwekar M, Wei LS, Sharma R, Varghese R, Mohammed A.. Pathology, research and practice, 2026-02-24
Topic: Amyloid, tau and blood-test diagnosis
Background Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by accumulation of amyloid-β (Aβ) plaque, tangles of tau neurofibres, chronic neuroinflammation, and dysfunction of the blood brain barrier (BBB). Monoclonal antibodies targeting Aβ and tau have focused disease-modifying potential, but their clinical impact is limited in brain penetration, immunogenicity, amyloid-related imaging abnormalities (ARIA), high treatment costs, and the need for repeated intravenous administration. These limitations has lead to discover in antibody-based nanoparticle platforms as advanced delivery and diagnosis. Objective This review aims to evaluate antibody-based nanoparticles as emerging tools for the diagnosis and treatment of AD, focusing on nanoparticle design, antibody conjugation strategies, mechanisms of BBB transport, immune modulation, and current translational challenges. Current evidence Recent preclinical studies reflects that antibody-functionalized nanoparticles can improve target specificity, enhance BBB transport by receptor-mediated and adsorptive transcytosis, and modulate neuroinflammatory responses by microglial Fc-receptor engagement. Advances in nanoparticle materials including gold, magnetic iron oxide, polymeric, and lipid-based systems has applications in both therapy and molecular imaging using MRI and PET. Critical barriers including nanoparticle instability, immune clearance, antibody denaturation after conjugation, long-term toxicity, manufacturing scalability, and regulatory uncertainty for hybrid biologic nanomaterial products exist. Conclusion Antibody-based nanoparticles represent promising but still evolving platform for precision diagnostics and targeted therapy in AD. While preclinical evidence is encouraging, successful clinical translation depends on standardized manufacturing, comprehensive safety evaluation, and well-designed trials. Future efforts focus on theranostic systems, multi-target antibody platforms addressing pathology, and regulatory frameworks supporting scalable and reproducible nanoparticle-based interventions.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Patwekar, F., Patwekar, M., Wei, L. S., Sharma, R., Varghese, R., & Mohammed, A. (2026). Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy. Pathology, research and practice. https://doi.org/10.1016/j.prp.2026.156421
Vancouver
Patwekar F, Patwekar M, Wei LS, Sharma R, Varghese R, Mohammed A. Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy. Pathology, research and practice. 2026. doi:10.1016/j.prp.2026.156421. PMID: 41762606.
BibTeX
@article{patwekar2026-41762606,
author = {Patwekar, F. and Patwekar, M. and Wei, L. S. and Sharma, R. and Varghese, R. and Mohammed, A.},
title = {{Antibody-based nanoparticles in Alzheimer's disease: Innovations in diagnosis and therapy}},
journal = {Pathology, research and practice},
year = {2026},
doi = {10.1016/j.prp.2026.156421},
pmid = {41762606},
url = {https://doi.org/10.1016/j.prp.2026.156421}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Advances in nanoparticle materials including gold, magnetic iron oxide, polymeric, and lipid-based systems has applications in both therapy and molecular imaging using MRI and PET.
- Critical barriers including nanoparticle instability, immune clearance, antibody denaturation after conjugation, long-term toxicity, manufacturing scalability, and regulatory uncertainty for hybrid biologic nanomaterial products exist.
- Conclusion Antibody-based nanoparticles represent promising but still evolving platform for precision diagnostics and targeted therapy in AD.
- While preclinical evidence is encouraging, successful clinical translation depends on standardized manufacturing, comprehensive safety evaluation, and well-designed trials.
- Future efforts focus on theranostic systems, multi-target antibody platforms addressing pathology, and regulatory frameworks supporting scalable and reproducible nanoparticle-based interventions.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record and multi-centre collaboration, so those were left out: it earned 25 of the 58 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Pathology, research and practice) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41762606) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 25 / 58 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 25 of the 58 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments
Also tagged “nanoparticles”
2 studies in the library carry the topic tag “nanoparticles”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 2 tagged studies.